Maybe you could tell us where you know about this "joint filing" to the EMA. Are you implying that Insmed has suggested at any time that they would try and get 2 different indications done with two different trials and combine them into an approval for 2 indications? We look forward to your answer with novelty.
From today's 10k: "We expect to submit regulatory filings with the EMA and Health Canada in the middle of 2014. If the EMA allows a filing that includes both the CF and NTM indication we will most likely submit our filing in the second half of 2014."